Chung-Liang Li
Overview
Explore the profile of Chung-Liang Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kan J, Shih S, Yang S, Chu P, Chen F, Li C, et al.
Int J Mol Sci
. 2024 Jan;
25(2).
PMID: 38279296
Exosomal microRNAs (miRNAs) are novel, non-invasive biomarkers for facilitating communication and diagnosing cancer. However, only a few studies have investigated their function and role in the clinical diagnosis of breast...
2.
Tsai J, Li C, Yeh D, Hung C, Hung C, Lin C, et al.
Breast Cancer Res Treat
. 2023 Mar;
199(1):47-55.
PMID: 36869992
Purpose: This study aimed to compare the effectiveness and safety of pegylated liposomal doxorubicin (PLD)-based and epirubicin-based combination therapy regimen as neoadjuvant therapy for early breast cancer. Methods: Patients with...
3.
Li C, Moi S, Lin H, Hou M, Chen F, Shih S, et al.
Int J Mol Sci
. 2022 Sep;
23(18).
PMID: 36142451
Endocrine therapy (ET) of selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and aromatase inhibitors (AIs) has been used as the gold standard treatment for hormone-receptor-positive (HR+) breast...
4.
Ou-Yang F, Li C, Chen C, Shen Y, Moi S, Luo C, et al.
Am J Cancer Res
. 2022 Feb;
12(1):123-137.
PMID: 35141008
The atezolizumab (Tecentriq), a humanized antibody against human programmed death ligand 1 (PD-L1), combined with nab-paclitaxel was granted with accelerated approval to treat unresectable locally advanced or metastatic triple-negative breast...
5.
Li C, Wu C, Kan J, Chen F, Hou M, Chuang C, et al.
Kaohsiung J Med Sci
. 2021 Nov;
38(3):277-282.
PMID: 34825475
This study aimed to investigate the effectiveness of neoadjuvant chemotherapy in patients with breast cancer in different age groups and evaluate the impact of age group on survival outcome according...
6.
Pan M, Wu C, Kan J, Li Q, Chang S, Wu C, et al.
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771753
In the original article [...].
7.
Hou M, Ou-Yang F, Li C, Chen F, Chuang C, Kan J, et al.
Exp Mol Med
. 2021 Oct;
53(10):1636-1646.
PMID: 34707191
In Western countries, breast cancer tends to occur in older postmenopausal women. However, in Asian countries, the proportion of younger premenopausal breast cancer patients is increasing. Increasing evidence suggests that...
8.
Kuo C, Kan J, Kao C, Ou-Yang F, Wu C, Shiau J, et al.
Clin Case Rep
. 2021 Oct;
9(10):e04716.
PMID: 34631060
NPWT fulfill graft taking in complex breast wounds.
9.
Kan J, Moi S, Hung W, Hou M, Chen F, Shih S, et al.
Genes (Basel)
. 2020 Dec;
11(12).
PMID: 33260650
Hypersialylation caused by the overexpression of sialyltransferases (STs) is a common feature in cancer that is associated with several characteristics of tumorigenesis. Thus, identifying cancer-associated STs is critical for cancer...
10.
Li C, Huang C, Ko C, Fang S, Ou-Yang F, Pan M, et al.
Anticancer Res
. 2020 Sep;
40(10):5529-5538.
PMID: 32988876
Background/aim: Triple-negative breast cancer (TNBC) is a unique subtype that lacks expression of several conventional biomarkers and has a higher incidence of lymph node invasion and distal metastasis among all...